Abstract
In Denmark, Alzheimer drugs have been registered since 1997. Three cholinesterase inhibitors (donepezil, rivastigmin og galantamin) are approved mild to moderate Alzheimer's disease and one partial NMDA receptor antagonist (memantin) with the indication moderate to severe Alzheimer's disease. The treatment is symptomatic with a parallel shift of the course. The life expectancy does not seem to be altered. There is documented effect on the cholinesterase inhibitors of up to two years and for memantine for 6 months. New disease modifying agents are under clinical development.
MeSH terms
-
Activities of Daily Living
-
Alzheimer Disease / drug therapy*
-
Alzheimer Disease / psychology
-
Cholinesterase Inhibitors / adverse effects
-
Cholinesterase Inhibitors / therapeutic use*
-
Clinical Trials as Topic
-
Cognition / drug effects
-
Dementia, Vascular / drug therapy
-
Disease Progression
-
Donepezil
-
Evidence-Based Medicine
-
Galantamine / adverse effects
-
Galantamine / therapeutic use
-
Humans
-
Indans / adverse effects
-
Indans / therapeutic use
-
Lewy Body Disease / drug therapy
-
Memantine / adverse effects
-
Memantine / therapeutic use
-
Nootropic Agents / adverse effects
-
Nootropic Agents / therapeutic use*
-
Parkinson Disease / drug therapy
-
Phenylcarbamates / adverse effects
-
Phenylcarbamates / therapeutic use
-
Piperidines / adverse effects
-
Piperidines / therapeutic use
-
Randomized Controlled Trials as Topic
-
Rivastigmine
-
Treatment Outcome
Substances
-
Cholinesterase Inhibitors
-
Indans
-
Nootropic Agents
-
Phenylcarbamates
-
Piperidines
-
Galantamine
-
Donepezil
-
Rivastigmine
-
Memantine